Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

The collaboration with Merck KGaA, Darmstadt, Germany focuses on discovering ... including with respect to the progress and ...

InProcess-LSP are a young organization, founded in 2014, they have since emerged as providers of groundbreaking process analytical technology for nanoparticle characterization. This article provides a ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

“Merck’s legacy spans over 33 years here in ... The announcement follows last year’s €3m investment in Livingston as part of the design, development and commercialisation of a novel ...